Erasca crashes 48% on 7x volume after patient death in pancreatic cancer trial
Erasca (ERAS) fell 48% day-over-day — touching an intraday low of $8.70, a 54% drop from its prior close of $19.15 — before closing at $9.90, after a patient in its pancreatic cancer trial died following severe lung inflammation. The session erased roughly $2.9 billion in market value from a stock that had surged more than 400% year-to-date.
Supporting 8 queries
To surface this insight, Baselight ran 8 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
Close $9.90 vs prior close $19.15 (−48.3%); intraday low $8.70 (−54.6%); volume 51.2M vs 20-day avg 7.0M (7.3x); 52-week high $22.47 set days earlier; ~$2.9B market-cap wiped in one session.